A recent scientific publication and strategic financial maneuvers are generating significant momentum for InnoCan Pharma. The company has announced pivotal data supporting its upcoming FDA application, alongside preparations for a potential US stock market listing, positioning the biotech firm for a potential revaluation.
Publication Validates Sustained Drug Delivery Platform
New research findings for InnoCan’s LPT-CBD technology have been published in the peer-reviewed journal Precision Nanomedicine. The study demonstrated that a single subcutaneous injection resulted in detectable CBD concentrations in blood plasma for a remarkable 28-day period.
Key findings from the research include:
- Extended Release Profile: Plasma CBD levels remained measurable for up to four weeks following a single administration.
- Human-Like Metabolic Pathway: Test subjects exhibited high levels of the metabolite 7-COOH-CBD, indicating a metabolic process closely mirroring that observed in humans.
- Favorable Safety Data: No adverse effects or localized reactions at injection sites were reported throughout the entire study duration.
Strategic Positioning for FDA Approval Pathway
The significance of these results is amplified by the animal model utilized. Regulatory authorities consider the Göttingen Minipigs used in this study the “gold standard” for safety assessments due to their pronounced anatomical and physiological similarities to humans. Company management views these outcomes as a robust foundation for initiating further pharmacokinetic studies under regulatory oversight.
Should investors sell immediately? Or is it worth buying InnoCan Pharma?
This successful toxicity study represents the completion of essential testing required before entering the formal FDA approval process. Furthermore, InnoCan has already secured alignment with the US Food and Drug Administration on its non-clinical development plan. The validation in this animal model has substantially de-risked the subsequent phases of human clinical trials.
US Listing Initiative Gains Traction
Concurrent with these scientific achievements, InnoCan is actively advancing its corporate strategy. Reports confirm the company is collaborating with New York-based investment bank ThinkEquity to prepare for a potential Initial Public Offering in the United States.
This strategic initiative is clearly aimed at raising fresh capital. The forthcoming registration studies represent a significant financial undertaking, and a US listing could provide the necessary liquidity to fund them. Investors are now tasked with evaluating the reduced scientific risk against the inherent execution risks that persist within the volatile biotechnology sector.
Ad
InnoCan Pharma Stock: Buy or Sell?! New InnoCan Pharma Analysis from November 21 delivers the answer:
The latest InnoCan Pharma figures speak for themselves: Urgent action needed for InnoCan Pharma investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 21.
InnoCan Pharma: Buy or sell? Read more here...
